ATG-010(Selinexor) in Combination With Chemotherapy in RRMM

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 21, 2021

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Multiple Myeloma
Interventions
DRUG

Selinexor (80mg/d)

"Selinexor (ATG-010) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm I:80mg/d QW ;"

DRUG

Selinexor (100mg/d)

"Selinexor (ATG-010) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm II:100mg/d QW ;"

DRUG

Pegylated liposomal doxorubicin

25 mg/m\^2 intravenously on day 1 , QW

DRUG

Dexamethasone

Dexamethasone 40mg/d QW

DRUG

Cyclophosphamide

Cyclophosphamide:300mg/m2, d1 QW,

Trial Locations (5)

430022

RECRUITING

Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan

430071

NOT_YET_RECRUITING

Zhongnan Hospital of Wuhan University, Wuhan

450000

RECRUITING

Henan Cancer Hospital, Zhengzhou

710000

NOT_YET_RECRUITING

The First Affiliated Hospital of Air Force Medical University, Xi’an

710004

NOT_YET_RECRUITING

The Second Affiliated Hospital of Xi'an Jiaotong University, Xi’an

All Listed Sponsors
lead

Chunyan Sun, MD

OTHER